<DOC>
	<DOC>NCT01639495</DOC>
	<brief_summary>This is a prospective, multicenter, non-randomized continued access clinical evaluation utilizing the THERMOCOOL® SMARTTOUCH™ catheter.</brief_summary>
	<brief_title>THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS</brief_title>
	<detailed_description>The device is currently under investigation with IDE #G110030. This continued access study will enroll subjects that have participated in the Smart-AF IDE study. Subjects with drug refractory symptomatic paroxysmal atrial fibrillation (PAF) will be considered for this study. Effectiveness and safety endpoints have been defined and will be evaluated post treatment.</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Have had at least 3 atrial fibrillation episodes within 6 months of this study Have failed at least one antiarrhythmic drug shown by repeated atrial fibrillation episodes 18 years of age or older Exclusion Criteria including, but not limited to: Have had previous ablation for atrial fibrillation Have take amiodarone within 6 months of this study Have had any heart surgery within the last 60 days Have had a heart attack within the last 60 days Females who are pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Drug refractory</keyword>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Antiarrhythmic drug failure</keyword>
	<keyword>Atrial tachyarrhythmias</keyword>
</DOC>